Transcripta Bio
Transcripta Bio is a pioneering drug discovery company leveraging a proprietary AI-driven platform that integrates high-throughput transcriptomic data and machine learning to map chemical structures to gene expression changes. Their platform screens thousands of molecules across 20,000 genes to build a comprehensive Drug-Gene Atlas, enabling prediction and synthesis of novel drug candidates that modulate cellular functions. This approach accelerates discovery across multiple diseases, including rare genetic disorders, by linking molecular structure directly to cellular behavior and patient biology. The company operates a high-fidelity lab for rapid synthesis and validation of compounds, supported by AI models trained on extensive transcriptomic datasets. Transcripta Bio's business model focuses on developing innovative therapies through a closed-loop system combining wet lab experiments and in silico predictions, positioning it as a leader in scalable, high-certainty drug discovery with partnerships in biopharma and patient foundations.
Transcripta Bio
Transcripta Bio is a pioneering drug discovery company leveraging a proprietary AI-driven platform that integrates high-throughput transcriptomic data and machine learning to map chemical structures to gene expression changes. Their platform screens thousands of molecules across 20,000 genes to build a comprehensive Drug-Gene Atlas, enabling prediction and synthesis of novel drug candidates that modulate cellular functions. This approach accelerates discovery across multiple diseases, including rare genetic disorders, by linking molecular structure directly to cellular behavior and patient biology. The company operates a high-fidelity lab for rapid synthesis and validation of compounds, supported by AI models trained on extensive transcriptomic datasets. Transcripta Bio's business model focuses on developing innovative therapies through a closed-loop system combining wet lab experiments and in silico predictions, positioning it as a leader in scalable, high-certainty drug discovery with partnerships in biopharma and patient foundations.